IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

:

Joseph A. Bauer

:

Serial No.

10/761,870

Group Art Unit: Not Yet Assigned

Filed:

January 21, 2004

Examiner: Not Yet Assigned

For:

COMPOSITION AND METHOD FOR AFFECTING

METALLOCORRINOID UPTAKE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Mail Stop DD P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. Copies are provided. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to deposit account no. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

Raymond a Meller

Raymond A. Miller

Registration No. 42,891

Pepper Hamilton LLP One Mellon Bank Center 50th Floor 500 Grant Street Pittsburgh, PA 15219 Telephone: (412) 454-5813

Facsimile: (412) 281-0717

Date: April 6, 2004

/2	JC6	
(0)	KR 28 20	W 100 100 100 100 100 100 100 100 100 10
	PATER	

					<u> </u>	Complete is	f Known	
Substitute	for form	n 1449/PTO			Application N	umber	10/761,870	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date First Named Inventor		January 21, 2004			
					Bauer			
			Group Art Unit		Not yet assigned			
	(use	as many sheets as neces	sary)		Examiner Nam	ne	Not yet assigned	
Sheet	1	of 3			Attorney Dock	et Number	126233.110	
	<u>,</u>		τ	J.S. PATENT	DOCUMENTS		1 310 1	*
Examiner's Initials	Cite No.	U.S. Patent Document Number Kind Code		Name of Patentee or Applicant of Cited Document		Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		(if kno		· v		MM-DD-YYYY	_	
	AA	5,936,082		Bauer		08-10-1999		
	AB	6,096,290		Collins et al.		02-06-2001		
	AC	6,183,723		Seetharam et		02-06-2001		- Silve 10
1 - 1	C't	I F D D			NT DOCUMEN			T m
Examiner's Initials	Cite No.	Foreign Patent Docume Office Number Kind C	ode		tee or Applicant of Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	. T
	ВА	EP 0220030	B1	Europe		10-10-1986		+
		OTHER ART	(Inc	luding Author,	Title, Date, Pert	inent Pages, Etc.)		· ·
Examiner's Initials	Cite No.	Include name of the author of magazine, journal, serial, sy where published.	in CAI	PITAL LETTERS	, title of the article (v	when appropriate), tit	le of the item (book,	T
	CA	cells. Blood 76, 1380-1386. (1990).					٠.	
	CB	Bauer, J.A. Synthesis, chara agent. Anticancer Drugs 9,	239-24	4. (1998).			<u> </u>	
	СС	Begley, J.A. & Hall, C.A. M						
	CD	Begley, J.A. & Hall, C.A. M 45, 287-293. (1975).	lasure (of vitamin B12-bir	iding proteins of plas	ma. II. Interpretation	of patters in disease. Blood	
	CE	Blomquist, L., Flodh, H. & Experientia 25, 294-296. (19		g, S. Uptake of lab	eled vitamin B 12 and	d 4-iodophenylalanin	e in some tumors of mice.	
	CF							
	CG	Bose, S., Seetharam, S., & Seetharam, B. Membrane expression and interactions of human transcobalamin II receptor. J. Biol. Chem 270, 8152-8157. (1995).						
	СН					-		
	CI	Bose, S., Felix, J., Seetharam, S. & Seetharam, B. Dimerization of transcobalamin II receptor. Requirement of a structurally ordered lipid bilayer. J. Biol Chem 271, 11718-11725. (1996).						
	CJ	Bose, S. & Seetharam, B. E. human intestinal epithelial C					and basolateral targeting in	1
	CK	Bose, S., Seetharam, S., Dahms, N.M. & Seetharam, B. Bipolar functional expression of transcobalamin II receptor in human intestinal epithelial Caco-2 cells. J. Biol Chem 272, 3538-3543. (1997).						
	CL	Bose, S. & Seetharam, B. Purification, membrance expression, and interactions of transcobalamin II receptor. Methods Enzymol 281, 281-289. (1997).						
	CM	Carmel, R. Extreme elevation of serum transcobalamin I in patients with metastatic cancer. N Engl J Med 292, 282-284. (1975).						
	CN	Chlichilia, K. et al. Caspace activation is required for nitric oxide-mediated, CD95 (APO-1/Fas)-dependent and independent apotosis in human neoplastic lymphoid cells. Blood 91, 4311-4320, (1998).				1		

				Complete if Known		
Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/761,870			
		Filing Date	January 21, 2004			
		First Named Inventor	Bauer			
		λ	Group Art Unit	Not yet assigned		
(use as many sheets as necessary))	Examiner Name	Not yet assigned	
Sheet	2	of 3		Attorney Docket Number	126233.110	
	CO Collins, D.A. et al. Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various			d with various malignancies.		
	СР	Mayo Clin Proc 75, 568-580. (2000). Cooper, B.A., e.a. Selectrive uptake of specifically bound cobalt-58 vitamin B12 by human and mouse tumor cells. N				
	CQ		f radioactive and no	onradioactive vitamin B12 in the dog.	Journal of Biological Chemistry	
	CR	235, 191-194. (1960). Cooperman, J. M. Distribution of	f radioactive and no	nradioactive vitamin B12 in normal an	nd malignant tissues of an infant	
		with neuroblastoma. Cancer Res	21, 167-172. (1972).		
	CS	DiGirolamo, P.M. & Huenneken: 386-393. (1975).	s, F.M. Transport of	f vitamin B12 into mouse leukemia cel	lls. Arch Biochem Biophys 168,	
	CT	Flodh, H. & Ullberg, S. Accumul	lation of labeled vit	amin B12 in some transplanted tumors	. Int J Cancer 3, 694-699. (1968).	
	CU	Gross, S.S. & Wolin, M.S. Nitric	oxide: pathophysic	ological mechanisms. Annu Rev Thysic	ol 57, 737-769. (1995).	
	CV	Huennekens, F.M., Digirolamo, I potential target for cancer chemo		bsen, D.W. & Vitols, K.S. B12-dependence Regul 14, 187-205. (1976).	dent methionine synthetase as a	
	CW	Jensen, H.S., Gimseing, P., Pedersen, F. & Hippe, E. Transcobalamin II as an indicator of activity in metastatic renal adenocarcinoma. Cancer 52, 1700-1704. (1983).				
	CX	Lindemans, J. et al. Uptake of transcobalamin II-bound cobalamin by HL-60 cells: effects of differentiation induction. Exp Cell Res 184, 449-460. (1989).				
	CY	McLean, G.R. et al. Cobalamin analogues modulate the growth of leukemia cells in vitro. Cancer Res 57, 4015-4022. (1997).				
	CZ	McLean, G.R., et al. Antibodies to transcobalamin II block in vitro proliferation of leukemic cells. Blood 89, 35-242. (1997).			ic cells. Blood 89, 35-242. (1997).	
	CAA	McLean, G.R., Williams, M.J., Woodhouse, C.S. & Ziltener, H.J. Transcobalamin II and in vitro proliferation of leukemic cells. Leuk Lymphoma 30, 101-109. (1998).				
	CAB	Panthare, P.M. et al. Synthesis of cobalamin-biotin conjugates that vary in the position of cobalamin coupling. Evalution of cobalamin derivative binding to transcobalamin II. Bioconjug Chem 7, 217-232. (1996).				
	CAC					
	CAD	Quadros, E.V. & Jacobsen, D.W. The dynamics of cobalamin utilization in L-1210 mouse leukemia cells: a model of cellular cobalamin metabolism. Biochim Biophys Acta 1244, 395-403. (1995).				
	CAE	Rabinowitz, R., Rachmilewitz, B., Rachmilewitz, M. & Schlesinger, M. Production of transcobalamin II by various murine and human cells in culture. Isr J Med Sci 18, 740-745. (1982).				
	CAF	Rigby, C.a.B., M. Experimental Study of the relationship between vitamin B12 and two animal tumor systems. Brit. J. Cancer 17, 90-99. (1963).				
	CAG	Ryel, E.M., Meyer, L.M. & Gams, R.A. Uptake and subcellular distribution of vitamin B12 in mouse L1210 leukemic lymphoblasts. Blood 44, 427-433. (1974).				
	CAH	I _ i _ i	<u> </u>	cobalamin (Vitamin B-12). J Nutr 129,	, 1761-1764. (1999).	
	CAI					
	CAJ	Shimizu, N., Hamazoe, R., Kanayama, H., Maeta, M. & Koga, S. Experimental study of antitumor effect of methyl-B12. Oncology 44, 169-173. (1987).				
	CAK				mobilized transcobalamin II by	
-	CAL		ng, M. Cytotoxic ac	tivity of cobalamin in cultured malign	ant and nonmalignant cells.	
	CAM		<u> </u>	n the survival of mice bearing ascites t	umor. Pathobiology 61, 104-108.	
	CAN				associated with hepatocellular	

		33 10 10 10	Comple	Complete if Known		
Substitute for form 1449/PTO			Application Number	10/761,870		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Filing Date	January 21, 2004		
			First Named Inventor	Bauer		
			Group Art Unit	Not yet assigned		
			Examiner Name	Not yet assigned		
Sheet	3	of 3	Attorney Docket Number	126233.110		
	CAO Zittoun, J., Zittoun, R., Marquet, J. & Sultan, C. The three transcobalamin in myeloproliferative disorders and acute leukemia. Br J Haematol 31, 287-298. (1975).					
Examiner Signature			Date Considered			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

APPLICANT:

Bauer

TITLE:

COMPOSITION AND METHOD FOR AFFECTING

METALLOCORRINOID UPTAKE

SERIAL NO.

10/761,870

ATTORNEY REF:

126233.110

DATE OF DEPOSIT:

April 6, 2004

I HEREBY CERTIFY THAT THIS INFORMATION DISCLOSURE STATEMENT WITH COPIES OF REFERENCES CITED THEREIN IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE VIA FIRST CLASS MAIL UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO COMMISSIONER FOR PATENTS, MAIL STOP DD, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Jennifer Martinez

(Typed br printed name of person mailing paper or fee)

Documents Enclosed:

- 1. Information Disclosure Statement with cited references;
- 2. Certificate of Mailing;
- 3. Postcard